Evidence and implications of pre-existing humoral cross-reactive immunity to SARS-CoV-2.
Immun Inflamm Dis
; 9(1): 128-133, 2021 03.
Article
in English
| MEDLINE | ID: covidwho-1064359
ABSTRACT
BACKGROUND:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged throughout the world. Building knowledge around Covid-19 is crucial to devise facts based approaches to respond efficiently against this pandemic.AIM:
We aimed to investigate pre-existing humoral cross-reactive immunity to SARS-CoV-2.METHOD:
We have tested the reactivity against SARS-CoV-2 nucleocapsid (N) antigen of sera collected from healthy healthcare volunteers in 2014. We assessed immunoglobulins reactive against SARS-CoV-2 N-antigen using a well-validated serological platform; Elecsys assay.RESULTS:
Sera from 32 subjects (out of 135 [23.7%]) were reactive to SARS-CoV-2 N-antigen, suggesting the presence of anti-SARS-CoV-2 N-antigen antibodies.CONCLUSION:
Although the clinical relevance of the observed reactivity can only be speculated and needs to be investigated, the implication of this finding for coronavirus disease 2019 seroepidemiological survey and vaccines' clinical trials is critical.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Cross Reactions
/
Host-Pathogen Interactions
/
Immunity, Humoral
/
SARS-CoV-2
/
COVID-19
Type of study:
Observational study
/
Prognostic study
/
Randomized controlled trials
Topics:
Vaccines
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Immun Inflamm Dis
Year:
2021
Document Type:
Article
Affiliation country:
Iid3.367
Similar
MEDLINE
...
LILACS
LIS